Cargando…

Update on the role of modified release mesalamine in the management of ulcerative colitis and Crohn’s disease

5-aminosalicyclates (5-ASA) remain a key first-line therapy for patients with ulcerative colitis (UC). A range of 5-ASA preparations is available and Eudragit-S(®) coated modified release formulations of mesalamine, such as Asacol(®), remain among the most popular choices. We here review the current...

Descripción completa

Detalles Bibliográficos
Autores principales:	Doherty, Glen A, Peppercorn, Mark A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2009
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3108647/ https://www.ncbi.nlm.nih.gov/pubmed/21694838

Ejemplares similares

Patient considerations in the management of ulcerative colitis: role of once-daily MMX mesalamine
por: Zandman, Daniel B, et al.
Publicado: (2009)

The role of mesalamine in the treatment of ulcerative colitis
por: Karagozian, Raffi, et al.
Publicado: (2007)

Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX(®) mesalamine
por: Nanda, Kavinderjit, et al.
Publicado: (2012)

Maintaining remission in ulcerative colitis – role of once daily extended-release mesalamine
por: Oliveira, Lilliana, et al.
Publicado: (2011)

Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX(®) mesalamine. [Corrigendum]
por: Nanda, K, et al.
Publicado: (2013)

Retrospective investigation of mesalamine intolerance in patients with ulcerative colitis
por: Minagawa, Yuki, et al.
Publicado: (2022)

Effectiveness of Mesalamine in Patients With Ulcerative Colitis: A Systematic Review
por: Santos, Yurianna, et al.
Publicado: (2023)

Myocarditis Secondary to Mesalamine-Induced Cardiotoxicity in a Patient with Ulcerative Colitis
por: Okoro, Kelechukwu U., et al.
Publicado: (2018)

High- and Low-Dose Oral Delayed-Release Mesalamine in Children With Mild-to-Moderately Active Ulcerative Colitis
por: Winter, Harland S., et al.
Publicado: (2014)

Genetic variants in cellular transport do not affect mesalamine response in ulcerative colitis
por: Moran, Christopher J., et al.
Publicado: (2018)

Once-daily MMX mesalamine for the treatment of mild-to-moderate ulcerative colitis
por: Kedia, Prashant, et al.
Publicado: (2007)

Mesalamine Intolerance in Three Children with Crohn's Disease
por: Tuna Kirsaclioglu, Ceyda, et al.
Publicado: (2016)

A Case of Right-Sided Ulcerative Colitis with Mesalamine-Induced Hypersensitivity Reactions
por: Hirono, Haruka, et al.
Publicado: (2018)

Urine Discoloration After Voiding in a Boy With Ulcerative Colitis Using Mesalamine
por: Zeef, Dagmar, et al.
Publicado: (2022)

Crohn's disease and ulcerative colitis Surgical management
por: Wilkinson, A J
Publicado: (1996)

Exacerbation of Bloody Diarrhea as a Side Effect of Mesalamine Treatment of Active Ulcerative Colitis
por: Shimodate, Yuichi, et al.
Publicado: (2011)

Randomized clinical trial: pharmacokinetics and safety of multimatrix mesalamine for treatment of pediatric ulcerative colitis
por: Cuffari, Carmen, et al.
Publicado: (2016)

Kangfuxinye Enema Combined with Mesalamine for Ulcerative Colitis: A Systematic Review and GRADE Approach
por: Ren, Peng-wei, et al.
Publicado: (2017)

A Case of Stevens–Johnson Syndrome Complicated with Multimatrix System Mesalamine in Ulcerative Colitis
por: Kanazawa, Mimari, et al.
Publicado: (2022)

Fulminant organizing pneumonia in a patient with ulcerative colitis on mesalamine and infliximab: striving to identify the cause!
por: Gomes, Lídia, et al.
Publicado: (2023)

The relationship among multiple patient-reported outcomes measures for patients with ulcerative colitis receiving treatment with MMX(®) formulated delayed-release mesalamine
por: Yarlas, Aaron, et al.
Publicado: (2014)

Editorial: Updates on ulcerative colitis and Crohn's disease: from bench to bedside
por: D'Andrea, Vito, et al.
Publicado: (2023)

Comparison of Concomitant Mesalamine and Immunomodulator Therapy and Immunomodulator Monotherapy for Crohn's Disease
por: Kwak, Min Seob, et al.
Publicado: (2018)

Natural History of Pediatric Patients With Crohn’s Disease Treated With Mesalamine Therapy
por: Young, Denise D., et al.
Publicado: (2023)

Mesalamine-Induced Myocarditis and Coronary Vasculitis in a Pediatric Ulcerative Colitis Patient: A Case Report
por: Perez-Colon, Elimarys, et al.
Publicado: (2011)

Long-Term Benefit of Mesalamine Granules for Patients Who Achieved Corticosteroid-Induced Ulcerative Colitis Remission
por: Lichtenstein, Gary R., et al.
Publicado: (2015)

The Efficacy and Safety of Mesalamine and Probiotics in Mild-to-Moderate Ulcerative Colitis: A Systematic Review and Meta-Analysis
por: Tian, Chunying, et al.
Publicado: (2020)

Gut Microbiota and Related Metabolites Were Disturbed in Ulcerative Colitis and Partly Restored After Mesalamine Treatment
por: Dai, Liang, et al.
Publicado: (2021)

19144 Effect of Mesalamine on Metabolic Syndrome risk factors in Ulcerative Colitis Patients: A Retrospective study
por: Castillo, Eliseo, et al.
Publicado: (2021)

Mucosal Barrier in Ulcerative Colitis and Crohn's Disease
por: Dorofeyev, A. E., et al.
Publicado: (2013)

Intrahepatic cholestasis in Bruton's agammaglobulinemia receiving mesalamine for co-morbid Crohn's disease
por: Actis, Giovanni Clemente, et al.
Publicado: (2014)

Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial
por: Rubin, David T., et al.
Publicado: (2017)

Recurrent Inflammatory Myositis as an Extra-Intestinal Manifestation of Dormant Ulcerative Colitis in a Patient on Long-Term Mesalamine
por: Naramala, Srikanth, et al.
Publicado: (2019)

Mucosal concentrations of N‐acetyl‐5‐aminosalicylic acid related to endoscopic activity in ulcerative colitis patients with mesalamine
por: Fukuda, Tomohiro, et al.
Publicado: (2020)

Is there a role for vedolizumab in the treatment of ulcerative colitis and Crohn’s disease?
por: Gilroy, Leah, et al.
Publicado: (2014)

Oral 5-Aminosalicylate, Mesalamine Suppository, and Mesalamine Enema as Initial Therapy for Ulcerative Proctitis in Clinical Practice with Quality of Care Implications
por: Richter, James M., et al.
Publicado: (2016)

The safety of vedolizumab for ulcerative colitis and Crohn's disease
por: Colombel, Jean-Frédéric, et al.
Publicado: (2017)

Ulcerative Colitis and Crohn's Disease: Similarities and Distinctions
por: Sawyerr, Af M, et al.
Publicado: (1994)

Review of pregnancy in Crohn’s disease and ulcerative colitis
por: Laube, Robyn, et al.
Publicado: (2021)

Nephrotic syndrome after treatment of Crohn's disease with mesalamine: Case report and literature review
por: Firwana, Belal M., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_fmd3bsal02lre36ptm8i17e6lj